Daniel West Research by SuperAGI

Daniel West

Chief Executive Officer, Prospection

LinkedIn Profile: [Daniel West - Prospection](https://au.linkedin.com/in/danieljameswest)

Professional Background

Daniel West is a technology industry executive with over 20 years of leadership experience in shaping go-to-market strategy, sales, and revenue operations. He is currently the Chief Executive Officer (CEO) of Prospection, a pioneer in patient-centric intelligence. Appointed on September 26, 2023, Daniel brings a distinguished track record in driving business growth and building successful teams across global technology organizations.

Previous Experience

Daniel has held several senior leadership roles at major industry players including:

MYOB

Oracle

Salesforce

Informatica

Throughout his career, Daniel has been instrumental in global commercialization advancements and AI innovations, leveraging technologies such as large language models (LLMs) and machine learning (ML) to enhance diagnostic, predictive, and prescriptive analytics.

Role at Prospection

At Prospection, Daniel is focused on propelling continued business growth and innovation. His leadership is pivotal in advancing global commercialization efforts and integrating artificial intelligence into Prospection’s suite of services. The aim is to elevate patient care and expand the company's market position through cutting-edge technology solutions.

Strategic Vision

Daniel has expressed a strong commitment to Prospection’s mission of delivering the right treatment to the right patients at the right time. His strategic vision includes:

Enhancing global strategy with a focus on AI and ML innovation.

Empowering pharmaceutical commercial leaders to improve patient care and market share through patient-centric intelligence.

Driving advancements in diagnostic, predictive, and prescriptive analytics to understand, diagnose, predict, and prescribe better health outcomes.

Board and Leadership Additions

Under Daniel’s leadership, Prospection has also strengthened its board with technology and pharmaceutical industry veterans:

Craig Jones as Chairperson of the Board, who brings a wealth of experience from guiding technology companies to achieve global potential and facilitating successful acquisitions.

Bruce Goodwin as Non-Executive Director, with over three decades of biopharmaceutical industry experience, enhancing Prospection’s capabilities in global drug commercialization and patient-centric approaches.

Industry Impact and Innovation

Daniel's deep understanding of technology trends and software commercialization provides Prospection with invaluable insights as the company aims to boost its AI-forward technology and healthcare analytics. This approach solidifies Prospection's stance as a healthcare partner of choice, maximizing the impact on patient care and market share through innovative AI solutions.

Future Prospects

Daniel's appointment is expected to drive significant growth for Prospection, leveraging its decade-long standing in the industry and its advanced AI capabilities. By focusing on patient-centric intelligence, the company aims to unlock the power of AI to transform healthcare outcomes and maintain its competitive edge in the market.

Professional Insights

Daniel's articles and participation in discussions, such as those on LinkedIn and various industry forums, provide valuable thought leadership. He frequently emphasizes the role of technology in healthcare and its disruptive potential to revolutionize patient care.

For further detailed insights: